Literature DB >> 23322821

Breast cancer stem cells: an update.

Jabed Iqbal1, Pek Yoon Chong, Puay Hoon Tan.   

Abstract

Breast cancer is a significant cause of morbidity and mortality in women with a high incidence of recurrence or treatment failure. Growing evidence suggests that cancer stem cells (CSCs) most likely contribute to tumour progression, spread and therapy failure. However, despite extensive research and the tremendous clinical potential of such cells in possible therapeutic management, the real nature of CSCs remains an enigma. In this review, we discuss the fundamental properties and molecular target of CSCs and focus on recent advances regarding the identification of CSC markers with emphasis on breast cancer and the underlying molecular mechanism of CSC phenotypes. We also discuss experimental evidence of targeting molecular pathways in order to modulate breast CSC behaviour in tumourigenesis and the controversies associated with it that potentially weaken the CSC model in breast cancer and other cancers as well.

Entities:  

Keywords:  Breast Cancer; Cancer Stem Cells; Molecular Oncology

Mesh:

Substances:

Year:  2013        PMID: 23322821     DOI: 10.1136/jclinpath-2012-201304

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  20 in total

1.  Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells.

Authors:  Ji Na Kong; Qian He; Guanghu Wang; Somsankar Dasgupta; Michael B Dinkins; Gu Zhu; Austin Kim; Stefka Spassieva; Erhard Bieberich
Journal:  Int J Cancer       Date:  2015-04-27       Impact factor: 7.396

Review 2.  Cancer stem cells as a potential therapeutic target in breast cancer.

Authors:  Mingzhi Zhang; Zhaoming Li; Xudong Zhang; Yu Chang
Journal:  Stem Cell Investig       Date:  2014-07-16

3.  Association between inflammation and cancer stem cell phenotype in breast cancer.

Authors:  Young Ju Jeong; Hoon Kyu Oh; Sung Hwan Park; Jin Gu Bong
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

4.  Morusin inhibits human cervical cancer stem cell growth and migration through attenuation of NF-κB activity and apoptosis induction.

Authors:  Li Wang; Huijie Guo; Liuqi Yang; Lihua Dong; Caiyu Lin; Jie Zhang; Ping Lin; Xiujie Wang
Journal:  Mol Cell Biochem       Date:  2013-03-31       Impact factor: 3.396

5.  Differential CD133 expression distinguishes malignant from benign papillary lesions of the breast.

Authors:  Chih-Hung Lin; Chia-Hsing Liu; Chien-Hui Wen; Pei-Ling Ko; Chee-Yin Chai
Journal:  Virchows Arch       Date:  2014-11-30       Impact factor: 4.064

6.  A novel animal model for locally advanced breast cancer.

Authors:  Maria V Bogachek; Jung Min Park; James P De Andrade; Mikhail V Kulak; Jeffrey R White; Tong Wu; Philip M Spanheimer; Thomas B Bair; Alicia K Olivier; Ronald J Weigel
Journal:  Ann Surg Oncol       Date:  2014-10-18       Impact factor: 5.344

7.  Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker.

Authors:  Bo Lei; Xian-Yu Zhang; Jia-Peng Zhou; Guan-Nan Mu; Yi-Wen Li; You-Xue Zhang; Da Pang
Journal:  Tumour Biol       Date:  2016-09-14

8.  Ligand binding to anti-cancer target CD44 investigated by molecular simulations.

Authors:  Tin Trung Nguyen; Duy Phuoc Tran; Zung Hoang; Paolo Carloni; Phuc Van Pham; Chuong Nguyen; Mai Suan Li
Journal:  J Mol Model       Date:  2016-06-24       Impact factor: 1.810

9.  Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties.

Authors:  C-H Wang; P-J Wang; Y-C Hsieh; S Lo; Y-C Lee; Y-C Chen; C-H Tsai; W-C Chiu; S Chu-Sung Hu; C-W Lu; Y-F Yang; C-C Chiu; F Ou-Yang; Y-M Wang; M-F Hou; S-Sf Yuan
Journal:  Oncogene       Date:  2017-10-09       Impact factor: 9.867

10.  Sumoylation pathway is required to maintain the basal breast cancer subtype.

Authors:  Maria V Bogachek; Yizhen Chen; Mikhail V Kulak; George W Woodfield; Anthony R Cyr; Jung M Park; Philip M Spanheimer; Yingyue Li; Tiandao Li; Ronald J Weigel
Journal:  Cancer Cell       Date:  2014-05-15       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.